ATE466944T1 - Dns-sequenzen mit anti-repressor aktivität - Google Patents

Dns-sequenzen mit anti-repressor aktivität

Info

Publication number
ATE466944T1
ATE466944T1 AT06124481T AT06124481T ATE466944T1 AT E466944 T1 ATE466944 T1 AT E466944T1 AT 06124481 T AT06124481 T AT 06124481T AT 06124481 T AT06124481 T AT 06124481T AT E466944 T1 ATE466944 T1 AT E466944T1
Authority
AT
Austria
Prior art keywords
regulatory sequences
repressor activity
sequences
dns
dns sequences
Prior art date
Application number
AT06124481T
Other languages
English (en)
Inventor
Arthur Leo Kruckeberg
Arie Otte
Original Assignee
Chromagenics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01202581A external-priority patent/EP1273666A1/de
Application filed by Chromagenics Bv filed Critical Chromagenics Bv
Application granted granted Critical
Publication of ATE466944T1 publication Critical patent/ATE466944T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT06124481T 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor aktivität ATE466944T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01202581A EP1273666A1 (de) 2001-07-04 2001-07-04 Verfahren zur Selektion einer transkription-modulatierenden DNA-Sequenz unter Verwendung einem Vektor mit einem transkriptions-repressions-aktivem Element
US30319901P 2001-07-05 2001-07-05
US10/190,312 US7192741B2 (en) 2001-07-04 2002-07-05 DNA sequences comprising gene transcription regulatory qualities and methods for detecting and using such DNA sequences

Publications (1)

Publication Number Publication Date
ATE466944T1 true ATE466944T1 (de) 2010-05-15

Family

ID=47915807

Family Applications (8)

Application Number Title Priority Date Filing Date
AT05076209T ATE358183T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor aktivität
AT02741531T ATE343004T1 (de) 2001-07-04 2002-06-14 Verfahren zur selektion einer transkription- modulatierenden dna-sequenz unter verwendung einem vektor mit einem transkriptions-repressions-aktivem element
AT06124481T ATE466944T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor aktivität
AT06124482T ATE467682T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor aktivität
AT06124465T ATE474053T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor-aktivität
AT06124491T ATE466943T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor aktivität
AT06124470T ATE466941T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor-aktivität
AT06124475T ATE466942T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor aktivität

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT05076209T ATE358183T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor aktivität
AT02741531T ATE343004T1 (de) 2001-07-04 2002-06-14 Verfahren zur selektion einer transkription- modulatierenden dna-sequenz unter verwendung einem vektor mit einem transkriptions-repressions-aktivem element

Family Applications After (5)

Application Number Title Priority Date Filing Date
AT06124482T ATE467682T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor aktivität
AT06124465T ATE474053T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor-aktivität
AT06124491T ATE466943T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor aktivität
AT06124470T ATE466941T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor-aktivität
AT06124475T ATE466942T1 (de) 2001-07-04 2002-06-14 Dns-sequenzen mit anti-repressor aktivität

Country Status (22)

Country Link
US (9) US7192741B2 (de)
EP (8) EP1829971B1 (de)
JP (3) JP4500044B2 (de)
KR (2) KR100942117B1 (de)
CN (1) CN1266282C (de)
AT (8) ATE358183T1 (de)
AU (3) AU2002314629B2 (de)
BR (1) BRPI0210771B8 (de)
CA (2) CA2450020C (de)
CY (1) CY1107678T1 (de)
DE (8) DE60236331D1 (de)
DK (8) DK1829972T3 (de)
ES (8) ES2344070T3 (de)
HK (1) HK1068652A1 (de)
IL (4) IL159674A0 (de)
MX (1) MXPA03011801A (de)
NO (1) NO338477B1 (de)
NZ (1) NZ530218A (de)
PT (1) PT1600510E (de)
SG (1) SG143066A1 (de)
WO (1) WO2003004704A2 (de)
ZA (1) ZA200309599B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2344070T3 (es) 2001-07-04 2010-08-17 Chromagenics B.V. Secuencias de adn con actividad anti-represora.
ES2362273T3 (es) * 2002-06-14 2011-06-30 Chromagenics B.V. Método para la producción simultánea de múltiples proteínas; vectores y células para su uso en el mismo.
EP1513936A2 (de) 2002-06-14 2005-03-16 Chromagenics B.V. Verwendung von repression hemmende sequenzen in verfahren zur genexpression verbesserung
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
CA2965865C (en) 2002-07-18 2021-10-19 Merus N.V. Recombinant production of mixtures of antibodies
WO2004055215A1 (en) 2002-12-18 2004-07-01 Chromagenics B.V. A method for improving protein production
EP1572994B1 (de) 2002-12-20 2007-02-21 Chromagenics B.V. Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können
EP2395016A3 (de) 2003-05-30 2012-12-19 Merus B.V. Entwurf und Verwendung von gepaarten unterschiedlichen Regionen von spezifisch bindenden Molekülen
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
JP4749334B2 (ja) 2003-10-02 2011-08-17 クルセル ホランド ベー ヴェー 組換えアデノウイルス用パッケージング細胞
WO2005059149A2 (en) * 2003-12-12 2005-06-30 Chromagenics B.V. Improved protein production
DK1737971T3 (da) 2004-01-20 2017-11-13 Merus Nv Blandinger af bindingsproteiner
MXPA06014553A (es) * 2004-07-08 2007-03-12 Chromagenics Bv Secuencia novedosa para mejorar la expresion del acido nucleico.
WO2006018319A1 (en) * 2004-08-18 2006-02-23 Bayer Cropscience Gmbh Plants with increased plastidic activity of r3 starch-phosphorylating enzyme
US8039230B2 (en) 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
US20060195935A1 (en) 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
US20100136616A1 (en) * 2004-11-08 2010-06-03 Chromagenics B.V. Selection of Host Cells Expressing Protein at High Levels
US8999667B2 (en) 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
JP5291341B2 (ja) * 2004-11-08 2013-09-18 クロマジェニックス ベー ヴェー タンパク質を高レベルで発現する宿主細胞の選定
SI1809750T1 (sl) * 2004-11-08 2012-08-31 Chromagenics Bv Izbira gostiteljskih celic, ki imajo visok nivo izraĹľanja proteina
KR100984602B1 (ko) * 2004-11-18 2010-09-30 고쿠리츠다이가쿠호진 히로시마다이가쿠 유전자 증폭에 의해 형성된 반복서열로부터, 발현이 억제된단백질을 발현시키는 방법, 키트, 및 형질전환체
EP1996705B1 (de) 2006-03-20 2011-08-31 ChromaGenics B.V. Die expression verstärkende dna-fragmente, deren verwendung und verfahren zum finden dieser
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
JP2010515435A (ja) * 2007-01-08 2010-05-13 ミリポア・コーポレイション 遺伝子増幅を不要とする高発現細胞株
WO2010147464A1 (en) 2009-06-15 2010-12-23 Cellagenics B.V. Use of a cysteine synthesizing enzyme as selectable marker
US8566596B2 (en) 2010-08-24 2013-10-22 Cisco Technology, Inc. Pre-association mechanism to provide detailed description of wireless services
DK2611915T3 (da) 2010-09-01 2015-06-22 Cellagenics B V Nukleinsyrefragmenter fra en ribosomal proteinpromoter til forstærkning af genekspression
AU2013249985B2 (en) 2012-04-20 2017-11-23 Merus N.V. Methods and means for the production of Ig-like molecules
SG11201408646VA (en) 2012-07-06 2015-01-29 Genmab Bv Dimeric protein with triple mutations
ES2692951T3 (es) 2012-09-27 2018-12-05 Merus N.V. Anticuerpos IgG biespecíficos como acopladores de células T
US10417380B1 (en) 2013-12-31 2019-09-17 Mckesson Corporation Systems and methods for determining and communicating a prescription benefit coverage denial to a prescriber
US10489552B2 (en) 2014-02-14 2019-11-26 Mckesson Corporation Systems and methods for determining and communicating patient incentive information to a prescriber
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
KR20240042540A (ko) 2014-02-28 2024-04-02 메뤼스 엔.페. ErbB-2와 ErbB-3에 결합하는 항체
US10157262B1 (en) 2015-03-10 2018-12-18 Mckesson Corporation Systems and methods for determining patient financial responsibility for multiple prescription products
CA2991880A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
SI3365373T1 (sl) 2015-10-23 2021-08-31 Merus N.V. Vezne molekule, ki zaviranjo rast raka
US11514137B1 (en) 2016-03-30 2022-11-29 Mckesson Corporation Alternative therapy identification system
US10999224B1 (en) 2017-02-01 2021-05-04 Mckesson Corporation Method and apparatus for parsing an electronic message and constructing multiple differently prioritized messages therefrom
MX2019011660A (es) 2017-03-31 2019-11-18 Merus Nv Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
KR20200042485A (ko) 2017-08-09 2020-04-23 메뤼스 엔.페. EGFR 및 cMET에 결합하는 항체
US10862832B1 (en) 2018-07-24 2020-12-08 Mckesson Corporation Computing system and method for automatically reversing an action indicated by an electronic message
US11043437B2 (en) 2019-01-07 2021-06-22 Applied Materials, Inc. Transparent substrate with light blocking edge exclusion zone
US11562437B1 (en) 2019-06-26 2023-01-24 Mckesson Corporation Method, apparatus, and computer program product for providing estimated prescription costs
US11636548B1 (en) 2019-06-26 2023-04-25 Mckesson Corporation Method, apparatus, and computer program product for providing estimated prescription costs
EP3772518A1 (de) 2019-08-07 2021-02-10 Merus N.V. Modifizierte menschliche variable domänen
US20230104317A1 (en) * 2020-01-31 2023-04-06 The Board Of Trustees Of The Leland Stanford Junior University Systems and Methods to Identify Genetic Silencers and Applications Thereof
US11610240B1 (en) 2020-02-17 2023-03-21 Mckesson Corporation Method, apparatus, and computer program product for partitioning prescription transaction costs in an electronic prescription transaction
MX2022014208A (es) 2020-05-21 2022-12-07 Merus Nv Metodos y medios para la produccion de moleculas tipo ig.
US11587657B2 (en) 2020-09-04 2023-02-21 Mckesson Corporation Method, apparatus, and computer program product for performing an alternative evaluation procedure in response to an electronic message
CN113539357B (zh) * 2021-06-10 2024-04-30 阿里巴巴达摩院(杭州)科技有限公司 基因检测方法、模型训练方法、装置、设备及系统

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US719271A (en) * 1902-01-13 1903-01-27 Solomon P Smith Furnace.
US5610053A (en) 1993-04-07 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells
US5972605A (en) 1994-07-07 1999-10-26 Geron Corporation Assays for regulators of mammalian telomerase expression
AU699275B2 (en) * 1995-03-24 1998-11-26 Shionogi & Co., Ltd. DNA molecule relating to suppression of gene expression and novel protein
DE19539493A1 (de) * 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5773695A (en) 1996-01-26 1998-06-30 North Carolina State University Plant nuclear scaffold attachment region and method for increasing gene expression in transgenic cells
US6037525A (en) * 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
KR100795626B1 (ko) 1998-07-21 2008-01-17 코브라 바이오매뉴팩쳐링 피엘씨. 도처에 있는 염색질 개방 요소(유씨오이)를 포함하는폴리뉴클레오티드
US6872524B1 (en) 1998-08-14 2005-03-29 Chromagenics B.V. Method of detecting an expression-enhancing sequence
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6521419B1 (en) 1998-09-22 2003-02-18 Kanakaraju Koduri Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6395549B1 (en) 1998-10-22 2002-05-28 Medical College Of Georgia Research Institute, Inc. Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors
PT1210411E (pt) * 1999-08-25 2006-12-29 Immunex Corp Composições e métodos para cultura celular melhorada
US20030166042A1 (en) 2000-02-11 2003-09-04 Millennium Pharmaceuticals, Inc. Novel seven-transmembrane proteins/G-protein coupled receptors
US6586205B1 (en) 2000-02-11 2003-07-01 Millennium Pharmaceuticals, Inc. 43239 a novel GPCR-like molecule and uses thereof
AU2001290067B2 (en) 2000-09-20 2007-04-05 Emd Millipore Corporation Artificial ubiquitous chromatin opening elements (UCOE)
EP1273666A1 (de) 2001-07-04 2003-01-08 Chromagenics B.V. Verfahren zur Selektion einer transkription-modulatierenden DNA-Sequenz unter Verwendung einem Vektor mit einem transkriptions-repressions-aktivem Element
ES2344070T3 (es) 2001-07-04 2010-08-17 Chromagenics B.V. Secuencias de adn con actividad anti-represora.
EP1513936A2 (de) * 2002-06-14 2005-03-16 Chromagenics B.V. Verwendung von repression hemmende sequenzen in verfahren zur genexpression verbesserung
ES2362273T3 (es) * 2002-06-14 2011-06-30 Chromagenics B.V. Método para la producción simultánea de múltiples proteínas; vectores y células para su uso en el mismo.
WO2004055215A1 (en) 2002-12-18 2004-07-01 Chromagenics B.V. A method for improving protein production
EP1572994B1 (de) 2002-12-20 2007-02-21 Chromagenics B.V. Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können

Also Published As

Publication number Publication date
ES2344073T3 (es) 2010-08-17
DE60219221T2 (de) 2008-01-03
PT1600510E (pt) 2007-06-25
DE60236334D1 (de) 2010-06-17
DE60219221D1 (de) 2007-05-10
EP1404872A2 (de) 2004-04-07
JP2004533262A (ja) 2004-11-04
EP1806407B1 (de) 2010-05-05
ES2348174T3 (es) 2010-11-30
BRPI0210771B1 (pt) 2015-12-22
CN1266282C (zh) 2006-07-26
ES2344071T3 (es) 2010-08-17
EP1829971B1 (de) 2010-05-05
DK1845162T3 (da) 2010-08-16
CN1524128A (zh) 2004-08-25
EP1808488A2 (de) 2007-07-18
JP5014443B2 (ja) 2012-08-29
EP1808488A3 (de) 2007-11-14
ES2274045T3 (es) 2007-05-16
US20070128717A1 (en) 2007-06-07
US20030199468A1 (en) 2003-10-23
EP1829972B1 (de) 2010-05-12
DK1829972T3 (da) 2010-09-13
EP1806407A3 (de) 2008-06-04
US7736868B2 (en) 2010-06-15
DE60236331D1 (de) 2010-06-17
EP1829971A3 (de) 2008-06-04
KR100942116B1 (ko) 2010-02-12
EP1600510A2 (de) 2005-11-30
DK1829971T3 (da) 2010-08-16
AU2007234619A1 (en) 2007-12-13
EP1845162A1 (de) 2007-10-17
AU2011202193B2 (en) 2011-09-29
CA2450020C (en) 2013-08-13
JP2010131024A (ja) 2010-06-17
EP1842919B1 (de) 2010-05-05
AU2007234619B2 (en) 2011-06-02
ATE466943T1 (de) 2010-05-15
DE60215502T2 (de) 2007-08-30
ATE466942T1 (de) 2010-05-15
SG143066A1 (en) 2008-06-27
IL159674A0 (en) 2004-06-20
US20070026498A1 (en) 2007-02-01
ATE343004T1 (de) 2006-11-15
DK1806407T3 (da) 2010-08-16
EP1404872B1 (de) 2006-10-18
JP5014444B2 (ja) 2012-08-29
JP4500044B2 (ja) 2010-07-14
KR100942117B1 (ko) 2010-02-12
CA2812799A1 (en) 2003-01-16
EP1600510B1 (de) 2007-03-28
CA2812799C (en) 2016-01-26
US20070031934A1 (en) 2007-02-08
DE60236333D1 (de) 2010-06-17
ATE358183T1 (de) 2007-04-15
US20070037256A1 (en) 2007-02-15
US7749733B2 (en) 2010-07-06
US7736869B2 (en) 2010-06-15
ES2344072T3 (es) 2010-08-17
EP1842919A1 (de) 2007-10-10
US20070031935A1 (en) 2007-02-08
ATE474053T1 (de) 2010-07-15
EP1845162B1 (de) 2010-05-05
IL193374A (en) 2010-12-30
US7736870B2 (en) 2010-06-15
EP1829972A3 (de) 2007-10-24
KR20090037485A (ko) 2009-04-15
ATE467682T1 (de) 2010-05-15
WO2003004704A3 (en) 2003-10-16
ZA200309599B (en) 2006-05-31
DE60237048D1 (de) 2010-08-26
BRPI0210771B8 (pt) 2021-05-25
US20070031936A1 (en) 2007-02-08
ES2285630T3 (es) 2007-11-16
IL193373A (en) 2010-12-30
DE60236332D1 (de) 2010-06-17
NZ530218A (en) 2005-09-30
US7659094B2 (en) 2010-02-09
DK1404872T3 (da) 2007-02-19
CY1107678T1 (el) 2013-04-18
US20070031933A1 (en) 2007-02-08
JP2010131025A (ja) 2010-06-17
NO338477B1 (no) 2016-08-22
DK1600510T3 (da) 2007-06-25
MXPA03011801A (es) 2005-03-07
CA2450020A1 (en) 2003-01-16
AU2011202193A1 (en) 2011-06-02
AU2002314629B2 (en) 2007-08-30
EP1808488B1 (de) 2010-07-14
EP1829971A1 (de) 2007-09-05
IL159674A (en) 2009-02-11
US7192741B2 (en) 2007-03-20
WO2003004704A2 (en) 2003-01-16
DE60236379D1 (de) 2010-06-24
EP1829972A2 (de) 2007-09-05
ATE466941T1 (de) 2010-05-15
ES2344074T3 (es) 2010-08-17
DE60215502D1 (de) 2006-11-30
ES2344070T3 (es) 2010-08-17
US7662591B2 (en) 2010-02-16
US20070026499A1 (en) 2007-02-01
EP1806407A2 (de) 2007-07-11
US7951586B2 (en) 2011-05-31
HK1068652A1 (en) 2005-04-29
KR20090037960A (ko) 2009-04-16
DK1808488T3 (da) 2010-10-18
DK1842919T3 (da) 2010-08-16
BR0210771A (pt) 2004-07-13
US7655441B2 (en) 2010-02-02
EP1600510A3 (de) 2006-02-22
NO20040011L (no) 2004-03-03

Similar Documents

Publication Publication Date Title
ATE474053T1 (de) Dns-sequenzen mit anti-repressor-aktivität
CY1108211T1 (el) Προφυλακτικη και θεραπευτικη αγωγη των μολυσματικων, αυτοανοσων και αλλεργικων νοσων με ενωσεις βασης μονοσακχαριτη
DE60219969D1 (de) Methode zur Production von L-Aminosäuren mittels Bakterien der Gattung Escherichia
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
BR0113109A (pt) Anticorpos antil-il-12, composições, métodos e usos
DE60231665D1 (de) Agarwood aus kulturmässigem Anbau
DE60333205D1 (de) Histaminika zur behandlung von allergischer rhinitis
HUP0003564A2 (hu) Protein kinázok és alkalmazásuk
DE60131682D1 (de) Biologische bekämpfung von pflanzenkrankheiten
DE60036645D1 (de) Methoden zur identifizierung evolutionär signifikanter änderungen in polynukleotid- und polypeptidsequenzen in domestizierten pflanzen und tieren
ATE310392T1 (de) Verwendung von oxytocin zur stimulierung des pflanzenwachstums
DE60321443D1 (de) Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung
DE50203158D1 (de) Dna-expressionskonstrukt zur behandlung von infektionen mit leishmaniose
Jozsef Poisonings of animal origin Review article. 3. Poisonings by Arthropoda. 2. Arachnida
ITBZ20020033A1 (it) Procedimento e impianto per il trattamento di piante lungo filari.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1845162

Country of ref document: EP